Aligned Genetics Inc (238120) — Cash Flow-to-Debt Ratio
Aligned Genetics Inc (238120) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-2.04 Billion could theoretically repay 0% of its total liabilities (₩9.61 Billion) in one year. See 238120 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aligned Genetics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Aligned Genetics Inc across 10 annual periods. For the full cash flow conversion analysis, see Aligned Genetics Inc (238120) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Aligned Genetics Inc (2015–2024)
Year-by-year debt coverage analysis for Aligned Genetics Inc. Check earnings quality score of Aligned Genetics Inc to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | ₩3.07 Billion | ₩8.78 Billion | ▲ +17.9% |
| 2023 | 0.30x | ₩2.85 Billion | ₩9.62 Billion | ▲ +7.3% |
| 2022 | 0.28x | ₩2.22 Billion | ₩8.05 Billion | ▲ +1417.9% |
| 2021 | 0.02x | ₩135.97 Million | ₩7.48 Billion | ▲ +104.8% |
| 2020 | 0.01x | ₩35.67 Million | ₩4.02 Billion | ▼ -95.1% |
| 2019 | 0.18x | ₩659.29 Million | ₩3.65 Billion | ▲ +121.8% |
| 2018 | -0.83x | ₩-1.75 Billion | ₩2.11 Billion | ▼ -57.3% |
| 2017 | -0.53x | ₩-876.75 Million | ₩1.67 Billion | ▲ +22.6% |
| 2016 | -0.68x | ₩-1.14 Billion | ₩1.68 Billion | ▼ -53.8% |
| 2015 | -0.44x | ₩-351.72 Million | ₩796.04 Million | — |